| |
Week 1
|
Week 2
|
Week 3
|
|---|
| |
Liver
|
Spleen
|
Liver
|
Spleen
|
Liver
|
Spleen
|
|---|
|
Con
|
48.15 ± 0.17
|
4.61 ± 0.99
|
48.61 ± 1.99
|
4.55 ± 1.12
|
47.87 ± 5.65
|
4.62 ± 0.41
|
|
PL16
|
48.26 ± 0.18
|
3.54 ± 1.54
|
48.49 ± 1.88
|
3.44 ± 1.02
|
42.91 ± 5.32
|
3.61 ± 0.88
|
|
TL16
|
54.35 ± 2.80
|
4.75 ± 0.86
|
52.65 ± 1.05
|
4.98 ± 1.50
|
46.56 ± 9.01
|
5.65 ± 0.81
|
|
Mod
|
58.18 ± 1.14**
|
4.67 ± 1.78
|
56.18 ± 5.37**
|
4.76 ± 1.83
|
51.77 ± 4.70
|
5.06 ± 0.97
|
- The data is presented by ratio of organ to body weight by mean ± SD. (**, p < 0.05).
- Groups are matched with experimental design in Method section. Con: the control group with orally administration of PBS. PL16: the protection group with administration of L16 strain before Staphylococcus aureus infection. TL16: the treatment group with administration of L16 strain after Staphylococcus aureus infection. Mod: murine model group with Staphylococcus aureus infection daily for 1 week.
